This paper describes the first multi-centre performance of a P ms based guidance device, Navigator™, in the task of guiding the circulation for postoperative open heart surgery patients. The device takes physiological data from standard bedside monitors and continuously converts it into graphical therapeutic guidance towards physiciandetermined blood and oxygen flow and MAP goals. The primary objective was to show that CO and MAP targets could be gained and maintained as well, or better, with device guidance as with conventional care.
MATERIALS AND METHODS
The prospective randomised controlled trial of the guidance system was conducted in the intensive care units (ICU) of six tertiary Australian hospitals. Approval for the trial was obtained from the ethics committee of each participating site. The Therapeutic Goods Administration (Australia) was notified of each trial site under the Clinical Trial Notification scheme, pursuant to Schedule SA of Regulation 12 of the Therapeutic Goods Regulations 1990.
In only one centre (Monash Medical Centre, Melbourne) had the device been used previously. None of the centres routinely practised protocoldriven haemodynamic care and the use of interventions such as fluids, cardioactives or vasoactives was based on clinician perceived patient requirements.
Guidance system
The guidance system was provided to participating centres for the duration of the trial. The software acquires data from a range of vendors' bedside physiological monitors, including heart rate, MAP, CO, RAP and arterial oxygen saturation (S a O 2 ). Transducers were levelled to a written standard phlebostatic axis. Five-secondly input data was filtered, artefacts rejected, 'park bench' averaged over 30 seconds and logged.
Numerical algorithms estimated volume state (P ms, mmHg ), where P ms =0.96×RAP+0.04×MAP+c×CO
where c is a scaling variable with the dimensions of resistance dependent upon patient height, weight and age 10 .
Heart performance (E h , dimensionless ) was calculated as along with systemic vascular resistance (SVR), oxygen delivery index and other derived variables [8] [9] [10] . E h quantifies the separation of P ms and RAP which is the driving pressure for venous return. An E h of 0 represents no cardiac function and a RAP equal to P ms . Note that E h is reasonably insensitive to minor inaccuracy in the measurement of RAP, especially in the important low range of E h (pump failure). If for example P ms =18 and RA=13, then If RAP was in fact 14 and MAP, CO unchanged, P ms would equal 19 and The graphical display of the guidance device provides a visual representation of the patient's circulatory situation in relation to clinician defined haemodynamic targets (CO and MAP). In order to avoid the complexity of a three-dimensional display, volume state (P ms ) and heart performance (E h ), both determinants of heart power (Power= [MAP-RAP]×CO) are plotted on two independently moving vertical axes ( Figure 1 ). The systemic vascular resistance, the determinant of how power is partitioned between pressure and flow, is plotted on the moving horizontal axis. The three axes are driven to maintain the target values of the therapeutic states in the centre of the display.
The patient's present haemodynamic position with respect to the three axes is plotted and displayed with an included 'arrow' which shows the direction of the therapeutic responses required to take MAP and CO together towards targets ( Figure 1 ). The absolute value of E h and the change in E h in response to P ms change are prime measures of volume responsiveness, a major determinant of whether to use volume or cardioactive drugs for positive vertical movement. Staff in this study were instructed to use E h alone in this regard (especially E h <0.3) and volume responsiveness was not displayed. An E h of less than 0.3 was suggested as a value at which clinical input should be considered to decide on the need for investigations (such as echocardiography) to exclude potential reversible causes of heart failure and consider the utility of further volume therapy to increase CO or MAP (as opposed to cardioactives). 
Patients
Open heart surgery patients were chosen as in local practice they routinely have pulmonary artery catheters placed preoperatively, enabling reliable measurement of the cardiac output. Patients over 18 years of age scheduled to undergo elective valve or coronary artery surgery on cardiopulmonary bypass were screened. Patients had a continuous CO pulmonary artery catheter inserted (Vigilance™, Edwards, CA, USA). All patients provided preoperative written consent and were without relevant contraindication. Patients were excluded if they were pregnant or lactating, had chronic atrial fibrillation (AF), had undergone surgical intervention for AF or left atrial reduction, had a permanent pacemaker in situ, received postoperative mechanical circulatory support with a ventricular assist device, or extracorporeal membrane oxygenation. Patients with a history of chronic AF were excluded, as we were interested in the possible effect of improved control on the incidence of new AF post heart surgery. AF in no way invalidates the principles of device operation.
Procedures
Staff at each site received training in the use of the guidance device. Rostered ICU bedside staff made all clinical decisions. Eligible patients were admitted postoperatively to ICU for 1:1 nursing care and connected to bedside monitoring In the case of the mean blood pressure and cardiac output/index the physician-entered targets for these values were adjacent (ranges were automatically set). Anthropometric values (age, height, weight) and current haemoglobin were entered to this panel, allowing display of current and target oxygen delivery indices (DO 2 I) using the measured arterial oxygen saturation. The left side of the screen was the navigation screen displaying primary therapeutic axes. There were two independently moving vertical axes, the volume P ms (mmHg) axis and the heart performance E h (E h =[P ms -RAP]/P ms , dimensionless) axis. The horizontal axis was the familiar systemic vascular resistance axis ([dyn.s.cm -5 ]/100). The axes moved to keep the target values at the centre. The target values for MAP and CO set by the clinician were displayed as a centred yellow quadrilateral target zone ± 12% of the centre MAP and ± 15% of the centre CO target values respectively. Standardisation of the target zone was for the purposes of the trial only. The position of the patient was denoted by a red dot and on the vertical and horizontal axes by a red bar. A yellow 'arrow' at the patient position displayed the next desired therapeutic direction to take the patient monotonically in MAP and CO to the target. An upward component to the arrow indicated the need for a higher volume state or greater heart performance. The managing team could set a heart performance or volume responsiveness trigger for commencement of inotropic agents or pacing. A downward component would indicate stopping volume therapy, consideration of diuretics, reducing inotropic therapy if present and occasionally using agents such as beta-blockers.Transverse components to the arrow indicate logical manipulation of vasodilators and constrictors. In the example shown, guidance indicates the need for volume (the heart performance is above the inotropic trigger) and gentle arterial vasodilatation. MAP=mean arterial pressure, CO=cardiac output, CI=cardiac index, RAP=right atrial pressure. equipment for RAP, CO, MAP and pulmonary artery pressure monitoring. Serial communication with the guidance device was established. Patients were medically assessed. Study number, age, height, weight and target values for CO, oxygen delivery index and MAP were entered using the touch-screen interface.
Patients were then randomly assigned to guided care (guidance) or conventional care (control) in a 1:1 ratio by entering a code obtained from a centralised telephone system. Randomisation was stratified by centre and prior history of episodic AF, and took place within one hour postoperatively. The study period extended from randomisation to the cessation of CO monitoring and removal of the pulmonary artery catheter.
Staff caring for patients in the guidance group received continuous graphical representation of patient position in relation to target and guidance for the use of volume, cardioactive and vasoactive interventions. A defined target zone was standardised to ± 12% of the centre MAP target and ± 15% of the centre CO target. This provided a consistent guide of proximity to target.
Compliance with guidance was not mandatory and was not monitored. In the event that different CO and MAP targets were deemed preferable by bedside staff, target values in both groups could be altered throughout the study period. These changes to target values were recorded.
For patients randomised to the control arm the guidance screen remained blank ( Figure 2 ), and the target centre values for CO and MAP were documented at the bedside in the standard manner for that site. Changes to target values for CO and MAP were manually documented. The use of volume, inotropic and vasoactive interventions in this group was determined by medical and nursing staff according to usual clinical practice but not recorded as part of the study.
Endpoints
The primary endpoint was a single combined measure of the unsigned (absolute) error between actual and target values of MAP and CO integrated over the study period and referred to as the 'average standardised distance' (ASD). The ASD is a measure of the attainment and maintenance of both MAP and CO together in relation to the physiciandetermined targets. The difference between actual and targeted values was standardised by dividing each error by the half-width of the target ranges for MAP and CO as appropriate.
sMAP= abs (actual MAP-target MAP) abs (target MAP-window edge e MAP) where s=standardised, abs=absolute.
Standardisation was undertaken so that the contributions from MAP and CO to the combined measure of error were equal. The ASD was then calculated as the geometric distance from the centre of the target zone to the position determined by the two standardised measures.
An actual MAP or CO value on the boundary of the target zone therefore had an ASD of unity. A lower value of ASD represented better attainment of target values for MAP and CO.
Secondary endpoints were the percentage of time in the target zone during the study period and the accumulated sign, but not the trajectory or frequency of excursions. Clinical secondary endpoints were the incidence of AF both in the study period and up to hospital discharge, daily multiple organ dysfunction (Sequential Organ Failure Assessment [SOFA]) scores 11 and device-related adverse events. Using SOFA, six organ systems are scored 0 to 4 (4 worst); mean and highest daily (0 to 24) SOFA scores are predictors of outcome.
Sample size calculation
Based on a pilot study of comparable patients at a single trial centre, the mean ASD of patients receiving circulation guidance was 0.98 (SD=0.7). A sample size of 50 patients per treatment group would therefore provide sufficient power (80%) to show a 30% improvement in ASD with the use of guidance (two-tailed alpha=0.05). Sufficient patients were to be consented to allow 100 patients to complete the study (50 in each treatment arm).
Statistical analysis
The primary endpoint and the percentage of time in the target zone were analysed on all patients randomised and connected to the guidance system for a minimum of three hours (modified intention to treat population). The other secondary endpoints and all safety data were analysed on the intention to treat population.
The primary efficacy endpoint was compared between the two treatment groups using independent t-tests and was summarised as the mean and 95% confidence interval (CI) of the difference (controlguidance). The relative status of the guidance compared to control (superior or non-inferior) was to be inferred from this confidence interval. Non-inferiority was defined as the lower 95% confidence limit of the difference being greater than -10% of the control mean for the primary endpoint. There was no measure of the safety of the trajectory taken to target.
The secondary efficacy endpoints were compared between the two randomised treatment groups using independent t-tests for the percentage time in the target zone and daily SOFA scores. Chi-square tests and Fisher's exact tests were used for the incidence of AF.
Adverse events were coded and tabulated using the latest version of the MedDRA system 12 .
Treatment-emergent adverse events were tabulated as the proportion of patients experiencing an event type by body system, by relationship to study device and by severity. Serious adverse events were summarised separately. Concomitant medications were coded using the World Health Organization dictionary and summarised by preferred term using frequencies and percentages.
All clinical safety data were listed for each patient. The clinical significance of laboratory values which were outside the laboratory's normal range was also listed. Vital signs were tabulated and summarised by treatment arm as frequencies, percentages, means, medians and ranges. No formal statistical comparisons of any of these safety measures were made between the two randomised treatment arms.
RESULTS
A total of 147 patients were screened. Thirty-five did not meet inclusion criteria (most commonly because they did not have a pulmonary artery catheter inserted at operation). Screening failure patients were not included in the database. Thus 112 patients were randomised; 59 patients received guided care and 53 conventional care during the ICU stay. These 112 patients comprised the intentionto-treat population and were analysed for adverse events. Demographics and procedures were well balanced between the groups (Table 1) .
Primary endpoint
Of the 59 patients who received guided care, two were withdrawn from the study prior to completion; one on day zero because of cardiac tamponade (not device-related) and one on day one due to (not device-related) death. Of the 53 patients who received conventional care, three were withdrawn; one because of a protocol violation and two others on day zero because communication between the cardiac output monitor and guidance device could not be established. Of the 107 patients who completed sCO= abs (actual CO-target CO) abs (target CO-window edge CO) ) ASD= SMAP +SCO ( ) 2 2 the study as planned, 105 (57 in the guidance group and 48 in the control group) received at least three hours of therapy and formed the modified intentionto-treat population for efficacy analysis (ASD and Time in Target Zone). The primary outcome measure (ASD) for the entire study period and for each three-hour time period is given in Table 2 . Lower values for ASD indicate values for MAP and CO were closer to target. The primary endpoint measure (ASD) for the guidance group was 1.71 (SD=0.65) and the control group 1.92 (SD=0.98), (P=0.202). The difference of 10.9% (95% CI -5.7% worse to 27.1% better) was not statistically significant but the 95% confidence interval did satisfy our a priori test for non-inferiority. A trend to improved control in the Navigator arm was consistently observed within the hourly periods over the first 24 hours (Figure 3) .
Secondary endpoints and safety analysis
The mean percentage of time in the target zone was 38.4% (SD=17.6) and 32.4% (SD=21.0) for the guided and control arms respectively. The difference in mean percentage of time in the target cardiovascular zone was 6.0%, 95% CI (-1.5, 13.5, P=0.12).
The individual deviations of the CO and MAP from their target values are given in Table 2 and were similar in both groups. The availability of the guidance system did not delay time to removal of pulmonary artery catheter, or significantly change ICU or hospital length-of-stay (Table 3 ). There were no significant differences in the volume of fluid administered or lost by each group, nor in the number of patients in each group who received vasoactive or inotropic infusions ( Table 3) . Mean sequential organ failure scores were similar in the two groups on the first (guidance 5.9, SD=2.9, control 6.5, SD=3.4) and second (guidance 5.6, SD=2.5, control 6.7, SD=2.7) postoperative days and were significantly lower in the guidance group (6.0, SD=1.6) on the third day compared to control (9.2, SD=1.9) for the (only) seven patients remaining in the ICU (P=0.011).
The percentage of patients with clinically significant AF during connection was 5.08% and 5.77% for the guidance and control arms respectively. The difference in the percentage of patients with clinically significant AF during connection was 0.69% 95% CI (-8.93%, 11.11%) with a two-sided P value of 1.00 using Fisher's exact test. The percentage of patients with clinically significant AF during and after connection was 37.29% and 42.31% for the guidance and control arm respectively (difference 5.02%, 95% CI, 12.80 to 22.56%, P=0.59).
There were 80 changes to target values of CO and/or MAP after connection to the Navigator system in 37 patients in the guidance group, compared to 18 changes in 17 patients in the control group.
The rates of adverse events are given in Table 4 and were similar in both groups. There were no device-related adverse events. There were two deaths (unrelated to the device) during the study.
Exploratory analyses
There was a significant difference in the ASD between the six centres (F 5,98 =4.8, P=0.001). The difference between the mean ASD for control and guidance groups in each centre are given in Ear and labyrinth disorders 1 (1.7) 0 (0.0) 1 (0.9)
Hepatobiliary disorders 0 ( 0.0) 1 (1.9) 1 (0.9) Figure 4 : Absolute Advantage to Navigator™ by individual centre (each centre, then the combined result is listed separately along the X axis). Figure 4 . A positive difference represents an advantage to Navigator (absolute advantage). Four of the six centres recruited showed an advantage to the guided treatment group with a pooled advantage of 20% over conventional care in terms of ASD (Figure 4) . In one centre the conventional group showed an advantage over guided treatment.
A post hoc multivariate analysis of the first 12 hours of guidance compared to the entire study period demonstrated a greater advantage to guided treatment with respect to the primary measure of effectiveness (ASD) (1.67 for the guidance group and 1.92 for the control group, P=0.052) when adjusted for centre.
DISCUSSION
The aim of this work was to test the utility of a new generation monitoring device which incorporated a non-traditional, numerical approach to circulation control based on a venous return model and incorporating novel measures of the volume state and heart performance. Guidance in the treatment arm provided bedside staff in six different Australian centres with visual representation of the patient's haemodynamic status relative to target values and continual numerically based haemodynamic guidance to reach those target values. Since clinician-based cardiovascular control after open heart surgery is well established, a competing guidance system requires a sound theoretical basis for comparable performance.
The study demonstrated that numerical guidance was at least as accurate as standard clinical care with 1:1 nursing. There were no device-related serious adverse events, especially events related to device guidance. While not demonstrating statistically superior control between the two treatment arms for the primary endpoint, the difference between the two groups surpassed the a priori noninferiority limit. There was a strong trend towards superiority in analyses adjusted for centre heterogeneity.
Our primary endpoint (ASD) for this initial multicentre trial was chosen as a measure of the proximity of patient CO and MAP during the study period to target settings, as this is a fundamental test of a guidance system. The ASD was not intended to represent a patient or clinical outcome and our sample size was selected to detect a treatment effect on control rather than clinical outcomes. Positive (above target) and negative (below) errors were given equal weight in evaluating control though the physiological implications may be different. Such 'time integration of the error' is a standard evaluation technique in control engineering.
The study design was chosen to facilitate beside care and to provide the most robust evidence for any treatment effect observed due to the intervention. A case control design would have imposed more work on bedside staff and may not have accounted for the variability in patient physiology and therapeutic aims.
A number of correctable factors operated in this preliminary study to limit the demonstration of improved accuracy with guided care. Probably the greatest of these was the non-compliance with guidance. Explicit targeting of the circulation was not routine in this patient group at these centres and an acceptance of pressure and flow values above target ranges was common. Patients in both groups spent less than 40% of the study time within the target zone (± 12% for MAP and ± 15% for CO). For the overwhelming majority of the time, the outliers had blood pressures and/or cardiac outputs above target. While the average MAP over the study period for both groups was 7.3 mmHg above target, which would have been within the MAP boundaries of the Target Zone, on average the CO was approximately 1 litre per minute higher than the target in both groups. For the vast majority of patients this would have been outside the ± 15% boundaries for CO in the Target Zone. This had implications for our endpoints examining control.
The higher frequency of target change in the guidance group we believe was related to the simplicity of change and automatic recalculation of therapy. Targeting is to some extent a function of the present circulation and the therapy required to achieve it; it is an iterative process. It may from time to time have had the consequence of keeping the patient in the target zone. A clinical guidance system for control of CO would benefit from an accurate, rapidly responsive continuous CO signal. We chose a pulmonary artery CO monitor because of its agreement with intermittent thermodilution cardiac output, which is commonly considered the gold standard for CO estimation 13 . An inherent shortcoming of the Vigilance™ (Edwards Laboratories, Irvine, CA, USA) continuous cardiac output device was the delay caused by the signal epoch required for cross correlation of the pseudo-random binary heater signal and the thermistor response 14 . This resulted in a CO signal that was five or more minutes delayed, with obvious implication for derived signals using present variables (MAP, RAP etc.) and delayed CO. This would have short-term consequences for guidance advice and ASD calculation. The use of a calibrated arterial pressure waveform-based CO measurement 15 , in being fairly immediate, should resolve this issue.
There were significant performance differences between the participant hospitals in training, understanding and application. This was borne out in the results by centre. There were clear differences in favour of guidance in the integrated errors between the guidance and control groups in the best performing hospitals. It is clear that some clinicians had difficulty in understanding the guidance display. There were issues with labelling and orientation and the compression of a three-axis guidance into a twoaxis display. The display was not sufficiently intuitive. Though the guidance system ran on separate hardware in this study, the intention is that it be included as software in the primary monitor and would be more intuitive.
Traditionally, understanding of cardiovascular physiology starts with widely used but nonquantitative cardiocentric concepts such as inotropy and lusitropy, the relaxation properties of the heart in diastole. This historical approach has led to a descriptive rather than sound mathematical basis for the common practical requirement of controlling the abnormal circulation.
A clinical benefit of a circulatory guidance system is to more reliably and constantly achieve evidencebased goal directed therapies in a number of settings such as high risk surgery [16] [17] [18] and severe sepsis 5 . Reliance upon written protocols is conflicted by the requirements of simplicity and adaptability to variable physiological states. Translation of such protocols into routine practice therefore remains challenging with low acceptance 19, 20 .
Circulatory guidance systems could also reduce the burden of care. As ICUs increase in size there is an emerging need to at least partly automate the repetitive process of circulation therapy so that it is continually directed towards explicit pressure and flow targets. Computer-based point of care guidance systems have been used in a number of critical care settings [21] [22] [23] [24] . They can facilitate guidance incorporating complex patient state assessment and offer the possibility of closed loop control 10, 25, 26 . Thus far, the uptake has been low despite some evidence of clinical effectiveness 27, 28 .
Another possible clinical benefit of our approach is the development of volume responsiveness indices. In the present study, though the heart performance E h was continuously displayed, no specific indication was given as to when to stop using fluid and start using inotropes in cases of severe circulatory impairment. It is now clear that measurement of P ms and E h may permit measures of volume responsiveness in ways that, unlike pulse pressure variation and stroke volume variation, will not require positive pressure ventilation and a regular pulse. This will be separately reported. Future development of the guidance device will address these issues. Measurement of change in the burden of care was not undertaken in this study.
Guyton pointed out that the mean circulatory pressure was "the first measurable quantity that allows one to relate blood volume mathematically to the control of cardiac output and arterial pressure" 29 . As a corollary, the simple expedient of using the mean pressure in the systemic circulation and its derivatives to measure the volume state and global heart performance is a likely key to successful numerical circulatory guidance. This paper is an initial description of such an alternative approach to the control of circulatory dynamics.
A challenge remains to achieve the best integration between patient, carer and machine.
